A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Phase of Trial: Phase III
Latest Information Update: 04 Jul 2017
Price : $35 *
At a glance
- Drugs Omarigliptin (Primary) ; Glimepiride; Metformin; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 31 Aug 2018 Biomarkers information updated
- 16 Sep 2015 Results published in Merck AG media release.
- 16 Sep 2015 Results published in a Merck & Co media release.